{"entity":{"id":"nct05043922","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma","aka":[],"tldr":"A phase 2 trial of CYH33 in ovarian cancer, run by Haihe Biopharma Co., Ltd., active and no longer recruiting.","summary":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma is a phase 2 interventional study registered as NCT05043922 by Haihe Biopharma Co., Ltd., with 93 participants enrolled, started 2021-10-11 and due to reach its primary completion in 2024-07-31. Interventions recorded: CYH33.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05043922","url":"https://clinicaltrials.gov/study/NCT05043922"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","clear-cell-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cyh33"],"companies":["haihe-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05043922","phase":"2","setting":"A Phase II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of CYH33, a Selective PI3Kα Inhibitor in Patients With Recurrent/Persistent Ovary, Fallopian Tube or Primary Peritoneal Clear Cell Carcinoma","sponsor":"Haihe Biopharma Co., Ltd.","started":"2021-10-11","startedType":"actual","enrolled":93,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05043922/","neighbours":{"cancer":[{"id":"clear-cell-ovarian-cancer","kind":"cancer","name":"Clear cell ovarian cancer","route":"/cancers/clear-cell-ovarian-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"cyh33","kind":"drug","name":"CYH33","route":"/drugs/cyh33/"}],"company":[{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/"}]}}